Open AccessRetracted: Efficacy and Adverse Effects of ( R ) ‐ 9‐(2‐phosphonylmethoxypropyl)‐2,6‐diaminopurine in Feline Immunodeficiency Virus‐Infected Cats
Author(s) -
Justa N.,
Weber K.,
Klein D.,
Mueller R.S.,
SauterLouis C.,
Hartmann K.
Publication year - 2012
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2012.01007.x
Subject(s) - cats , medicine , feline immunodeficiency virus , adverse effect , placebo , anemia , clinical trial , hemoglobin , gastroenterology , human immunodeficiency virus (hiv) , virology , lentivirus , viral disease , pathology , alternative medicine
Background ( R ) ‐ 9‐(2‐phosphonylmethoxypropyl)‐2,6‐diaminopurine ( PMPDAP ) is active against feline immunodeficiency virus ( FIV ) in vitro, and is less toxic than other acyclic nucleoside phosphonates. Its efficacy in naturally infected cats has not been evaluated in large controlled studies. Hypothesis/Objectives PMPDAP is effective in naturally FIV ‐infected cats with minimal adverse effects. Animals Forty‐five privately owned cats naturally infected with FIV . Methods Prospective, randomized, placebo‐controlled, double‐blinded clinical study. Cats were randomly assigned to be treated with PMPDAP (25 mg/kg) daily, PMPDAP 3 times a week, or placebo for a period of 6 weeks. Results Administration of PMPDAP to FIV ‐infected cats did not lead to detectable improvements in clinical, virological, or immunological variables. Proviral load ( FIV copies/10 6 cells) did not change significantly during treatment (placebo group: from 9505 ± 10119 to 8564 ± 8615; PMPDAP 3 times a week: from 4818 ± 4426 to 5041 ± 6197; PMPDAP daily: from 3525 ± 5038 to 3167 ± 5824). There was a significant decrease of red blood cell counts (×10 12 /L) (from 8.91 ± 1.82 to 7.34 ± 1.79 in cats treated 3 times per week ( P < .001), and from 8.96 ± 1.13 to 6.01 ± 1.36 in cats treated daily ( P < .001)), as well as of packed cell volume, and hemoglobin in both groups receiving PMPDAP . Conclusions and Clinical Importance Administration of PMPDAP was not associated with significant improvements in clinical, immunological, or virological parameters, but treatment was associated with adverse effects, mainly anemia. Thus, PMPDAP , as administered in this study, cannot be recommended for treatment of FIV ‐infected cats.